AI Verdict
KAI has stronger fundamentals based on our AI analysis.
KALV vs KAI Fundamental Comparison
| Metric | KALV | KAI |
|---|---|---|
| Revenue | $13.7M | $1.1B |
| Net Income | $-158.9M | $102.0M |
| Net Margin | -1,160.0% | 9.7% |
| ROE | -934.8% | 10.4% |
| ROA | -46.7% | 6.0% |
| Current Ratio | 7.22x | 2.38x |
| Debt/Equity | 0.31x | 0.38x |
| EPS | $-2.97 | $8.65 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
KALV vs KAI: Frequently Asked Questions
Is KALV or KAI a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), KAI has stronger fundamentals. KALV is rated HOLD (45% confidence) while KAI is rated HOLD (72% confidence). This is not investment advice.
How does KALV compare to KAI fundamentally?
KalVista Pharmaceuticals, Inc. has ROE of -934.8% vs KADANT INC's 10.4%. Net margins are -1,160.0% vs 9.7% respectively.
Which stock pays higher dividends, KALV or KAI?
KALV has a dividend yield of N/A or no dividend while KAI has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in KALV or KAI for long term?
For long-term investing, consider that KALV has HOLD rating with 45% confidence, while KAI has HOLD rating with 72% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about KALV vs KAI?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For KALV vs KAI, the AI consensus favors KAI based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.